About Moberg Pharma 

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s asset, MOB-015, is a novel topical treatment for onychomycosis with market approval in 13 EU countries. MOB-015 is available in Sweden under the brand name Terclara®. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB). 

Press releases:

SEK 436m transaction in two tranches SEK 100m (June 2023) & SEK 336m (June 2024)  




  • MOB-015 has demonstrated world-leading ability to treat nail fungus
    • In two completed Phase 3 studies involving over 800 patients, 76% of patients became fungus free  
    • An additional ongoing US Phase 3 study based on completed Phase 3 studies, with limited risk, is being conducted to enable US approval and thereby strengthen further international sales opportunities 
    • The company aims to become the market leader with USD 250-500m potential global product sales 
  • Partnerships in place – potential milestones of USD 70m: Bayer (EU), Cipher Pharmaceuticals (Canada), DongKoo (Republic of Korea), Padagis (Israel), and Allderma (Scandinavia) 
  • Launch ongoing under brand name Terclara®
    • National approvals in 13 EU countries – 7 OTC, 6 Rx 
    • Proven commercial track record from Kerasal Nail® – built SEK 440m franchise with 30% market share in the US 
    • Commercialization process to be repeated for MOB-015 

Website: https://www.mobergpharma.com/investors 



Capital raise

SEK 336m

June 2024

Sole Global Coordinator